FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in Clear Cell Renal Cell Carcinoma: LITESPARK-022 Phase 3 Results
The FDA has approved belzutifan plus pembrolizumab as adjuvant treatment for ccRCC. LITESPARK-022: a 28% improvement in DFS, with 24-month DFS of 80.7% versus 73.7% (HR 0.72).
- 5 DK OKUMA